AYTU BIOPHARMA, INC (AYTU): auditor change — Aytu BioPharma dismisses Plante & Moran, appoints Grant Thornton as auditor

AYTU BIOPHARMA, INC

Dismissed Plante & Moran on Dec 12, 2022; reports had no adverse opinions but FY2022 included going concern explanatory paragraph.
Appointed Grant Thornton LLP as independent auditor for fiscal year 2023.
No disagreements on accounting principles; material weakness in impairment analysis previously reported and remediated.
Grant Thornton had not been consulted on any accounting matters prior to engagement.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

AYTU BIOPHARMA, INC dismissed Plante & Moran PLLC as its auditor.

Action: dismissal
Auditor: Plante & Moran PLLC
Successor: Grant Thornton LLP

Exact text from the filing

On December 12, 2022, the Audit Committee of the Board of Directors of Aytu BioPharma, Inc. (the “Company”) dismissed Plante & Moran PLLC (“Plante Moran”), as the Company’s independent registered public accounting firm.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

AYTU BIOPHARMA, INC engaged Grant Thornton LLP as its auditor.

Action: engagement
Auditor: Grant Thornton LLP

Exact text from the filing

On December 12, 2022, the Audit Committee appointed Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ended June 30, 2023.

View on SEC.gov

Browse all auditor changes →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-22-018607

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.